Stock Analysis

Three Stocks That May Be Priced Below Their Worth In November 2024

Published

Amidst a fluctuating global market landscape, marked by the return of some "Trump Trade" gains and sector-specific volatility, investors are keenly observing potential policy impacts on corporate earnings and regulatory shifts. In such an environment, identifying undervalued stocks can be crucial for those looking to capitalize on discrepancies between a company's market price and its intrinsic value.

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Giant Biogene Holding (SEHK:2367)HK$49.10HK$97.6749.7%
Wistron (TWSE:3231)NT$114.00NT$227.4849.9%
Business First Bancshares (NasdaqGS:BFST)US$27.67US$55.0749.8%
A.L.A. società per azioni (BIT:ALA)€24.80€49.5149.9%
Telix Pharmaceuticals (ASX:TLX)A$22.20A$44.2349.8%
EnomotoLtd (TSE:6928)¥1481.00¥2941.3049.6%
Enento Group Oyj (HLSE:ENENTO)€18.06€36.1150%
Intermedical Care and Lab Hospital (SET:IMH)THB4.96THB9.8749.7%
Saipem (BIT:SPM)€2.327€4.6550%
Nokian Renkaat Oyj (HLSE:TYRES)€7.39€14.6849.7%

Click here to see the full list of 918 stocks from our Undervalued Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Max Estates (NSEI:MAXESTATES)

Overview: Max Estates Limited engages in the construction and development of residential and commercial properties, with a market cap of ₹80.07 billion.

Operations: The company's revenue is primarily derived from its Real Estate Operations & Development segment, which generated ₹1.69 billion.

Estimated Discount To Fair Value: 38.5%

Max Estates is trading significantly below its estimated fair value of ₹814.96, with a current price of ₹501.25, suggesting it may be undervalued based on cash flows. Despite past shareholder dilution, revenue grew by 47.6% last year and is expected to grow at 27.5% annually, outpacing the Indian market's growth rate of 10.5%. The company anticipates becoming profitable within three years, offering potential for substantial future earnings growth despite a low forecasted return on equity.

NSEI:MAXESTATES Discounted Cash Flow as at Nov 2024

Middle East Healthcare (SASE:4009)

Overview: Middle East Healthcare Company operates a network of hospitals under the Saudi German Hospital brand in the Middle East and North Africa, with a market cap of SAR6.35 billion.

Operations: The company's revenue segments include Pharmacy Sales at SAR390.19 million, In Patient Services generating SAR1.62 billion, and Outpatient Services contributing SAR839.09 million.

Estimated Discount To Fair Value: 46%

Middle East Healthcare's current trading price of SAR 69 is considerably below its estimated fair value of SAR 127.7, highlighting potential undervaluation based on cash flows. Recent earnings showed a sales increase to SAR 732.07 million and net income growth to SAR 61.74 million, reflecting strong financial performance. Earnings are projected to grow at an impressive rate of over 21% annually, surpassing the Saudi Arabian market's growth expectations, although interest coverage remains a concern.

SASE:4009 Discounted Cash Flow as at Nov 2024

Strike CompanyLimited (TSE:6196)

Overview: Strike Company, Limited offers mergers and acquisitions brokerage services for small and medium-sized companies in Japan with a market cap of ¥72.78 billion.

Operations: The company's revenue is primarily derived from its M&A Intermediary Business, generating ¥18.14 billion.

Estimated Discount To Fair Value: 46.5%

Strike Company Limited's current price of ¥3,840 is significantly below its estimated fair value of ¥7,177.08, indicating potential undervaluation based on cash flows. The company forecasts robust revenue and earnings growth at rates surpassing the Japanese market averages. Recent guidance projects full-year net sales of ¥22.3 billion and profit of ¥5.63 billion for fiscal 2025, with a planned dividend increase to JPY 102 per share, reflecting strong financial health despite recent share price volatility.

TSE:6196 Discounted Cash Flow as at Nov 2024

Next Steps

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com